NDA 205572 · Fresenius Kabi USA
Moxifloxacin Hydrochloride
Moxifloxacin Hydrochloride · Intravenous
Last checked: Nov 20, 2026Latest source record: Mar 27, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Apr 3, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
648
93 Phase 3, 31 recruiting
FAERS reports
18,419
16,007 serious, 2,612 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1) ] , including: Tendinitis and tendon rupture [see Warnings and Precautions (5.2) ] Peripheral neuropathy [see Warnings and Precautions (5.3) ] Central nervous system effects [see Warnings and Precautions (5.4) ] Discontinue moxifloxacin immediately and avoid the use of fluoroquinolones, including moxifloxacin, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1) ] . Fluoroquinolones, including moxifloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid...
What it is approved for
From the label in effect Jul 17, 2024.
Moxifloxacin injection is a fluoroquinolone antibacterial drug indicated for treating infections in adults ≥ 18 years of age caused by designated, susceptible bacteria. ( 1 , 12.4 ) Community Acquired Pneumonia ( 1.1 ) Skin and Skin Structure Infections: Uncomplicated ( 1.2 ) and Complicated ( 1.3 ) Complicated Intra-Abdominal Infections ( 1.4 ) Acute Bacterial Sinusitis ( 1.5 ) Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.6 ) 1.1 Community Acquired Pneumonia Moxifloxacin Injection is indicated in adults (18 years of age or older) for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant isolates*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole [see Clinical Studies (14.2) ] . 1.2 Uncomplicated Skin and Skin Structure Infections Moxifloxacin Injection is indicated in adults (18 years of age or older) for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes [see Clinical Studies (14.5) ]. 1.3 Complicated Skin and Skin Structure Infections Moxifloxacin Injection is indicated in adults (18 years of age or older) for the treatment of Complicated Skin and Skin...
Mechanism: Moxifloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MOXIFLOXACIN HYDROCHLORIDE · MOXIFLOXACIN HYDROCHLORIDE EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Moxifloxacin" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract SurgeryPivotal-lookingNot yet recruiting
Jason Ahee, M.D.Industry
NCT03244072 · 60,000 participants (planned) · Start Jun 1, 2027 · Primary completion Oct 2030
Drug: Moxifloxacin; Placebo · For: Endophthalmitis
Sites: St. George, Utah
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.Pivotal-lookingTerminated
University of Campinas, BrazilAcademic, hospital or other
NCT02770729 · 3,640 participants · Start Jan 2017 · Primary completion Feb 2018
Drug: Moxifloxacin; No injection of moxifloxacin · For: Endophthalmitis
Sites: Campinas, Brazil
- TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening RegimensPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT02410772 · 2,516 participants · Start Jan 25, 2016 · Primary completion Jul 2020
Drug: rifapentine; rifapentine and moxifloxacin and 1 more · For: Tuberculosis
Sites: San Francisco, California; New York, New York; Fort Worth, Texas · 33 sites in all
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of TuberculosisPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT02563327 · 2,516 participants · Start Jan 25, 2016 · Primary completion Aug 30, 2021
Drug: Rifapentine; Moxifloxacin and 4 more · For: Tuberculosis
Sites: San Antonio, Texas; Kampala, Uganda; Hanoi, Vietnam
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
- Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary TuberculosisPivotal-lookingCompleted
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
NCT00864383 · 1,931 participants · Start Jan 2008 · Primary completion Oct 2013
Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin · For: Pulmonary Tuberculosis
Sites: Beijing, China; Shanghai, China; Tianjin, China · 47 sites in all
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02800785 · 1,552 participants · Start May 2016 · Primary completion Mar 5, 2020
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin · For: Appendicitis
Sites: Sylmar, California; Torrance, California; Aurora, Colorado · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,290
- dyspnoea2,218
- asthma2,143
- drug hypersensitivity2,083
- drug ineffective2,041
- pneumonia2,034
- vomiting1,882
- wheezing1,727
- pain1,699
- rash1,546
- fatigue1,405
- malaise1,308
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 36 |
| 2005 | 68 |
| 2006 | 41 |
| 2007 | 33 |
| 2008 | 22 |
| 2009 | 21 |
| 2010 | 111 |
| 2011 | 236 |
| 2012 | 250 |
| 2013 | 199 |
| 2014 | 263 |
| 2015 | 312 |
| 2016 | 787 |
| 2017 | 643 |
| 2018 | 1,132 |
| 2019 | 1,366 |
| 2020 | 1,541 |
| 2021 | 1,415 |
| 2022 | 1,683 |
| 2023 | 2,088 |
| 2024 | 2,388 |
| 2025 | 2,357 |
| 2026 | 1,427 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R, Popescu M, Gonong JR, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Effect of Topical Antibiotics on Duration of Acute Infective Conjunctivitis in Children: A Randomized Clinical Trial and a Systematic Review and Meta-analysis.
Honkila M, Koskela U, Kontiokari T, et al. · JAMA Netw Open 2022 · Meta-Analysis, Systematic Review
- Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Pettit AC, Phillips PPJ, Kurbatova E, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease.
Stocchi F, Peckham EL, De Pandis MF, et al. · Clin Pharmacol Drug Dev 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Lack of an Effect of Supratherapeutic Dose of Venlafaxine on Cardiac Repolarization in Healthy Subjects.
Abbas R, Riley S, Nepal S, et al. · Clin Pharmacol Drug Dev 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.